Prospects of a novel vaccination strategy for human gamma-herpesviruses

Immunologic Research

Volumn 48, Issue 1-3, 2010, Pages 122-146

  Wu, Ting Ting ^a,b   Blackman, Marcia A ^c   Sun, Ren ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c TRUDEAU INSTITUTE   (United States)

Author keywords

EBV; Gamma herpesviruses; KSHV; MHV 68; Vaccine

Indexed keywords

HERPES VACCINE; LIVE VACCINE;

ANIMAL; CELL TRANSFORMATION; DISEASE MODEL; GAMMAHERPESVIRINAE; GENETICS; HERPES VIRUS INFECTION; HUMAN; IMMUNE EVASION; IMMUNOLOGY; MOUSE; PATHOGENICITY; PHYSIOLOGY; REVIEW; VACCINATION; VIROLOGY; VIRUS CELL TRANSFORMATION; VIRUS INFECTION; VIRUS LATENCY; VIRUS REPLICATION;

ANIMALS; CELL TRANSFORMATION, NEOPLASTIC; CELL TRANSFORMATION, VIRAL; DISEASE MODELS, ANIMAL; GAMMAHERPESVIRINAE; HERPESVIRIDAE INFECTIONS; HERPESVIRUS VACCINES; HUMANS; IMMUNE EVASION; MICE; TUMOR VIRUS INFECTIONS; VACCINATION; VACCINES, ATTENUATED; VIRUS LATENCY; VIRUS REPLICATION;

EID: 79958725758     PISSN: 0257277X     EISSN: 15590755     Source Type: Journal    
DOI: 10.1007/s12026-010-8172-z     Document Type: Review

References (232)

1. Sokal EM, et al. Recombinant gp350 vaccine for infectious mononucleosis: a phase 2, randomized, double-blind, placebo-controlled trial to evaluate the safety, immunogenicity, and efficacy of an Epstein-Barr virus vaccine in healthy young adults. J Infect Dis. 2007;196(12):1749-53. (Pubitemid 351411934)
2. Jia Q, et al. Induction of protective immunity against murine gammaherpesvirus 68 infection in the absence of viral latency. J Virol. 2010;84(5):2453-65.
3. Stoopler ET. Oral herpetic infections (HSV 1-8). Dent Clin North Am. 2005;49(1):15-29. vii. (Pubitemid 39563607)
4. Levy JA. Three new human herpesviruses (HHV6, 7, and 8). Lancet. 1997;349(9051):558-63. (Pubitemid 27092804)
5. Rickinson AB, Kieff E. Epstein-Barr virus. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott Williams and Wilkins; 2001. p. 2575-628.
6. Roizman B, Pellet PE. The family herpesviridae: a brief introduction. In: Knipe DM, Howley PM, editors. Fields virology. Philadephia: Lippincott Williams & Wilkins; 2001. p. 2381-98.
7. Pass RF. Cytomegalovirus. In: Knipe DM, Howley PM, editors. Fields virology. Philadelphia: Lippincott Williams & Wilkins; 2001. p. 2675-706.
8. Cesarman E, et al. Kaposi's sarcoma-associated herpesvirus in non-AIDS related lymphomas occurring in body cavities. Am J Pathol. 1996;149(1):53-7. (Pubitemid 26230978)
9. Chang Y, et al. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994;266(5192):1865-9.
10. Brambilla L, et al. HHV8 cell-associated viraemia and clinical presentation of Mediterranean Kaposi's sarcoma. Lancet. 1996;347(9011):1338. (Pubitemid 26137820)
11. Corbellino M, et al. The role of human herpesvirus 8 and Epstein-Barr virus in the pathogenesis of giant lymph node hyperplasia (Castleman's disease). Clin Infect Dis. 1996;22(6):1120-1. (Pubitemid 26260634)
12. Corbellino M, et al. Restricted tissue distribution of extralesional Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS patients with Kaposi's sarcoma. AIDS Res Hum Retroviruses. 1996;12(8):651-7.
13. Soulier J, et al. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in multicentric Castleman's disease. Blood. 1995;86(4):1276-80.
14. Dedicoat M, Newton R. Review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma. Br J Cancer. 2003;88(1):1-3. (Pubitemid 36241209)
15. Wabinga HR, et al. Trends in cancer incidence in Kyadondo County, Uganda, 1960-1997. Br J Cancer. 2000;82(9):1585-92. (Pubitemid 30204367)
16. Bassett MT, et al. Cancer in the African population of Harare, Zimbabwe, 1990-1992. Int J Cancer. 1995;63(1):29-36.
17. Mbulaiteye SM, et al. Spectrum of cancers among HIV-infected persons in Africa: the Uganda AIDSCancer Registry Match Study. Int J Cancer. 2006;118(4):985-90. (Pubitemid 43157675)
18. Efstathiou S, Ho YM, Minson AC. Cloning and molecular characterization of the murine herpesvirus 68 genome. J Gen Virol. 1990;71(Pt 6):1355-64. (Pubitemid 20190472)
19. Virgin HWt, et al. Complete sequence and genomic analysis of murine gammaherpesvirus. J Virol. 1997;71(8):5894-904
20. Mackett M, et al. Genetic content and preliminary transcriptional analysis of a representative region of murine gammaherpesvirus. J Gen Virol. 1997;78(Pt 6):1425-33 (Pubitemid 27281345)
21. Sunil-Chandra NP, et al. Virological and pathological features of mice infected with murine gammaherpesvirus. J Gen Virol. 1992;73(Pt 9):2347-56
22. Doherty PC, et al. Tuning into immunological dissonance: an experimental model for infectious mononucleosis. Curr Opin Immunol. 1997;9(4):477-83. (Pubitemid 27392851)
23. Tripp RA, et al. Pathogenesis of an infectious mononucleosis-like disease induced by a murine gamma-herpesvirus: role for a viral superantigen? J Exp Med. 1997;185(9):1641-50. (Pubitemid 27203260)
24. Sunil-Chandra NP, et al. Lymphoproliferative disease in mice infected with murine gammaherpesvirus. Am J Pathol. 1994;145(4):818-26 (Pubitemid 24320599)
25. Tarakanova VL, et al. Murine gammaherpesvirus 68 infection is associated with lymphoproliferative disease and lymphoma in BALB beta2 microglobulin- deficient mice. J Virol. 2005;79(23):14668-79. (Pubitemid 41636265)
26. Lee KS, et al. Murine gammaherpesvirus 68 infection of IFNgamma unresponsive mice: a small animal model for gammaherpesvirus-associated B-cell lymphoproliferative disease. Cancer Res. 2009;69(13):5481-9.
27. Lau R, Middeldorp J, Farrell PJ. Epstein-Barr virus gene expression in oral hairy leukoplakia. Virology. 1993;195(2):463-74.
28. Katano H, et al. Expression and localization of human herpesvirus 8-encoded proteins in primary effusion lymphoma, Kaposi's sarcoma, and multicentric Castleman's disease. Virology. 2000;269(2): 335-44. (Pubitemid 30210906)
29. Staskus KA, et al. Cellular tropism and viral interleukin-6 expression distinguish human herpesvirus 8 involvement in Kaposi's sarcoma, primary effusion lymphoma, and multicentric Castleman's disease. J Virol. 1999;73(5):4181-7. (Pubitemid 29189863)
30. Sun R, et al. Kinetics of Kaposi's sarcoma-associated herpesvirus gene expression. J Virol. 1999;73(3):2232-42. (Pubitemid 29098128)
31. Nicholas J, et al. Kaposi's sarcoma-associated human herpesvirus-8 encodes homologues of macrophage inflammatory protein-1 and interleukin-6. Nat Med. 1997;3(3):287-92. (Pubitemid 27112925)
32. Cannon JS, et al. Heterogeneity of viral IL-6 expression in HHV-8-associated diseases. J Infect Dis. 1999;180(3):824-8. (Pubitemid 29411370)
33. Molden J, et al. A Kaposi's sarcoma-associated herpesvirus-encoded cytokine homolog (vIL-6) activates signaling through the shared gp130 receptor subunit. Journal of Biological Chemistry. 1997;272(31):19625-31. (Pubitemid 27337768)
34. Jones KD, et al. Involvement of interleukin-10 (IL-10) and viral IL-6 in the spontaneous growth of Kaposi's sarcoma herpesvirus-associated infected primary effusion lymphoma cells. Blood. 1999;94(8):2871-9. (Pubitemid 29477316)
35. Chang J, et al. Inflammatory cytokines and the reactivation of Kaposi's sarcoma-associated herpesvirus lytic replication. Virology. 2000;266(1):17-25. (Pubitemid 30048632)
36. An J, et al. Kaposi's sarcoma-associated herpesvirus encoded vFLIP induces cellular IL-6 expression: the role of the NF-kappaB and JNK/AP1 pathways. Oncogene. 2003;22(22):3371-85. (Pubitemid 36713734)
37. Nicholas J, et al. A single 13-kilobase divergent locus in the Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genome contains nine open reading frames that are homologous to or related to cellular proteins. J Virol. 1997;71(3):1963-74. (Pubitemid 27078575)
38. Moore PS, et al. Molecular mimicry of human cytokine and cytokine response pathway genes by KSHV. Science. 1996;274(5293):1739-44. (Pubitemid 26414912)
39. Sun R, et al. A viral gene that activates lytic cycle expression of Kaposi's sarcoma-associated herpesvirus. Proc Natl Acad Sci USA. 1998;95(18):10866-71.
40. Lukac DM, et al. Reactivation of Kaposi's sarcoma-associated herpesvirus infection from latency by expression of the ORF 50 transactivator, a homolog of the EBV R protein. Virology. 1998; 252(2):304-12. (Pubitemid 29013411)
41. Wu TT, et al. Rta of murine gammaherpesvirus 68 reactivates the complete lytic cycle from latency. J Virol. 2000;74(8):3659-67.
42. Ragoczy T, Heston L, Miller G. The Epstein-Barr virus Rta protein activates lytic cycle genes and can disrupt latency in B lymphocytes. J Virol. 1998;72(10):7978-84. (Pubitemid 28421790)
43. Countryman J, Miller G. Activation of expression of latent Epstein-Barr herpesvirus after gene transfer with a small cloned subfragment of heterogeneous viral DNA. Proc Natl Acad Sci USA. 1985; 82(12):4085-9. (Pubitemid 15052833)
44. Zalani S, Holley-Guthrie E, Kenney S. Epstein-Barr viral latency is disrupted by the immediate-early BRLF1 protein through a cell-specific mechanism. Proc Natl Acad Sci USA. 1996;93(17):9194-9. (Pubitemid 26282040)
45. Johannsen E, et al. Proteins of purified Epstein-Barr virus. Proc Natl Acad Sci USA. 2004;101(46):16286-91. (Pubitemid 39552837)
46. Zhu FX, et al. Virion proteins of Kaposi's sarcoma-associated herpesvirus. J Virol. 2005;79(2): 800-11. (Pubitemid 40053863)
47. Tanner J, et al. Epstein-Barr virus gp350/220 binding to the B lymphocyte C3d receptor mediates adsorption, capping, and endocytosis. Cell. 1987;50(2):203-13.
48. Nemerow GR, et al. Identification of gp350 as the viral glycoprotein mediating attachment of Epstein-Barr virus (EBV) to the EBV/C3d receptor of B cells: sequence homology of gp350 and C3 complement fragment C3d. J Virol. 1987;61(5):1416-20. (Pubitemid 17069728)
49. Thorley-Lawson DA, Geilinger K. Monoclonal antibodies against the major glycoprotein (gp350/220) of Epstein-Barr virus neutralize infectivity. Proc Natl Acad Sci USA. 1980;77(9):5307-11. (Pubitemid 11195555)
50. Hutt-Fletcher LM. Epstein-Barr virus entry. J Virol. 2007;81(15):7825-32. (Pubitemid 47101468)
51. Sixbey JW, Yao QY. Immunoglobulin A-induced shift of Epstein-Barr virus tissue tropism. Science. 1992;255(5051):1578-80.
52. Turk SM, et al. Antibodies to gp350/220 enhance the ability of Epstein-Barr virus to infect epithelial cells. J Virol. 2006;80(19):9628-33. (Pubitemid 44444661)
53. Gillet L, Stevenson PG. Evidence for a multiprotein gamma-2 herpesvirus entry complex. J Virol. 2007;81(23):13082-91. (Pubitemid 350156947)
54. Leight ER, Sugden B. EBNA-1: a protein pivotal to latent infection by Epstein-Barr virus. Rev Med Virol. 2000;10(2):83-100. (Pubitemid 30175424)
55. Barbera AJ, et al. Kaposi's sarcoma-associated herpesvirus LANA hitches a ride on the chromosome. Cell Cycle. 2006;5(10):1048-52. (Pubitemid 43765297)
56. Lee MA, Diamond ME, Yates JL. Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. J Virol. 1999;73(4):2974-82. (Pubitemid 29135686)
57. Ye FC, et al. Disruption of Kaposi's sarcoma-associated herpesvirus latent nuclear antigen leads to abortive episome persistence. J Virol. 2004;78(20):11121-9.
58. Fowler P, et al. ORF73 of murine herpesvirus-68 is critical for the establishment and maintenance of latency. J Gen Virol. 2003;84(Pt 12):3405-16. (Pubitemid 37540768)
59. Moorman NJ, Virgin HWt, Speck SH. Disruption of the gene encoding the gammaHV68 v-GPCR leads to decreased efficiency of reactivation from latency. Virology. 2003;307(2):179-90. (Pubitemid 36344154)
60. Wilson JB, Bell JL, Levine AJ. Expression of Epstein-Barr virus nuclear antigen-1 induces B cell neoplasia in transgenic mice. EMBO J. 1996;15(12):3117-26. (Pubitemid 26187759)
61. Fakhari FD, et al. The latency-associated nuclear antigen of Kaposi sarcoma-associated herpesvirus induces B cell hyperplasia and lymphoma. J Clin Invest. 2006;116(3):735-42. (Pubitemid 43326882)
62. Gires O, et al. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule. EMBO J. 1997;16(20):6131-40. (Pubitemid 27458333)
63. Miller CL, et al. Integral membrane protein 2 of Epstein-Barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity. 1995;2(2):155-66.
64. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells. Cell. 1985;43(3 Pt 2):831-40.
65. Thorley-Lawson DA. Epstein-Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1(1): 75-82. (Pubitemid 33741978)
66. Dittmer D, et al. A cluster of latently expressed genes in Kaposi's sarcoma-associated herpesvirus. J Virol. 1998;72(10):8309-15. (Pubitemid 28421829)
67. Sarid R, et al. Transcription mapping of the Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) genome in a body cavity-based lymphoma cell line (BC-1). J Virol. 1998;72(2):1005-12. (Pubitemid 28116878)
68. Sun Q, Zachariah S, Chaudhary PM. The human herpes virus 8-encoded viral FLICE-inhibitory protein induces cellular transformation via NF-kappaB activation. J Biol Chem. 2003;278(52): 52437-45. (Pubitemid 38035836)
69. Verschuren EW, et al. The role of p53 in suppression of KSHV cyclin-induced lymphomagenesis. Cancer Res. 2004;64(2):581-9. (Pubitemid 38120897)
70. Staskus KA, et al. Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol. 1997;71(1):715-9. (Pubitemid 26412345)
71. Zhong W, et al. Restricted expression of Kaposi sarcoma-associated herpesvirus (human herpesvirus 8) genes in Kaposi sarcoma. Proc Natl Acad Sci USA. 1996;93(13):6641-6. (Pubitemid 26230362)
72. Sadler R, et al. A complex translational program generates multiple novel proteins from the latently expressed kaposin (K12) locus of Kaposi's sarcoma-associated herpesvirus. J Virol. 1999;73(7): 5722-30. (Pubitemid 29274858)
73. Muralidhar S, et al. Identification of kaposin (open reading frame K12) as a human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus) transforming gene. J Virol. 1998;72(6):4980-8. (Pubitemid 28215678)
74. Husain SM, et al. Murine gammaherpesvirus M2 gene is latency-associated and its protein a target for CD8(+) T lymphocytes. Proc Natl Acad Sci USA. 1999;96(13):7508-13. (Pubitemid 29299692)
75. Rochford R, et al. Kinetics of murine gammaherpesvirus 68 gene expression following infection of murine cells in culture and in mice. J Virol. 2001;75(11):4955-63. (Pubitemid 32448515)
76. Marques S, et al. Selective gene expression of latent murine gammaherpesvirus 68 in B lymphocytes. J Virol. 2003;77(13):7308-18. (Pubitemid 36734499)
77. Martinez-Guzman D, et al. Transcription program of murine gammaherpesvirus. J Virol. 2003;77(19):10488-503
78. Virgin HWt, et al. Three distinct regions of the murine gammaherpesvirus 68 genome are transcriptionally active in latently infected mice. J Virol. 1999;73(3):2321-32.
79. Bowden RJ, et al. Murine gammaherpesvirus 68 encodes tRNA-like sequences which are expressed during latency. J Gen Virol. 1997;78(Pt 7):1675-87. (Pubitemid 27343108)
80. Flano E, et al. Latent murine gamma-herpesvirus infection is established in activated B cells, dendritic cells, and macrophages. J Immunol. 2000;165(2):1074-81. (Pubitemid 30484779)
81. Stewart JP, et al. Lung epithelial cells are a major site of murine gammaherpesvirus persistence. J Exp Med. 1998;187(12):1941-51. (Pubitemid 28285564)
82. Weck KE, et al. Macrophages are the major reservoir of latent murine gammaherpesvirus 68 in peritoneal cells. J Virol. 1999;73(4):3273-83. (Pubitemid 29135720)
83. van Dyk LF, Virgin HWt, Speck SH. Maintenance of gammaherpesvirus latency requires viral cyclin in the absence of B lymphocytes. J Virol. 2003;77(9):5118-26. (Pubitemid 36460926)
84. de Lima BD, et al. Murine gammaherpesvirus 68 bcl-2 homologue contributes to latency establishment in vivo. J Gen Virol. 2005;86(Pt 1):31-40.
85. Moorman NJ, Willer DO, Speck SH. The gammaherpesvirus 68 latency-associated nuclear antigen homolog is critical for the establishment of splenic latency. J Virol. 2003;77(19):10295-303. (Pubitemid 37129673)
86. Macrae AI, et al. Murid herpesvirus 4 strain 68 M2 protein is a B-cell-associated antigen important for latency but not lymphocytosis. J Virol. 2003;77(17):9700-9. (Pubitemid 37011063)
87. Stevenson PG, et al. K3-mediated evasion of CD8(+) T cells aids amplification of a latent gammaherpesvirus. Nat Immunol. 2002;3(8):733-40.
88. Jacoby MA, Virgin HWt, Speck SH. Disruption of the M2 gene of murine gammaherpesvirus 68 alters splenic latency following intranasal, but not intraperitoneal, inoculation. J Virol. 2002;76(4): 1790-801. (Pubitemid 34094627)
89. Loh J, et al. A surface groove essential for viral Bcl-2 function during chronic infection in vivo. PLoS Pathog. 2005;1(1):e10.
90. Fruh K, et al. Immune evasion by a novel family of viral PHD/LAP-finger proteins of gamma-2 herpesviruses and poxviruses. Virus Res. 2002;88(1-2):55-69. (Pubitemid 35251899)
91. Madureira PA, et al. Murine gamma-herpesvirus 68 latency protein M2 binds to Vav signaling proteins and inhibits B-cell receptor-induced cell cycle arrest and apoptosis in WEHI-231 B cells. J Biol Chem. 2005;280(45):37310-8. (Pubitemid 41642336)
92. Rodrigues L, et al. Activation of Vav by the gammaherpesvirus M2 protein contributes to the establishment of viral latency in B lymphocytes. J Virol. 2006;80(12):6123-35. (Pubitemid 43849190)
93. Siegel AM, Herskowitz JH, Speck SH. The MHV68 M2 protein drives IL-10 dependent B cell proliferation and differentiation. PLoS Pathog. 2008;4(4):e1000039.
94. Liang X, et al. Inhibition of interferon-mediated antiviral activity by murine gammaherpesvirus 68 latency-associated M2 protein. J Virol. 2004;78(22):12416-27. (Pubitemid 39458760)
95. Liang X, et al. Deregulation of DNA damage signal transduction by herpesvirus latency-associated M2. J Virol. 2006;80(12):5862-74. (Pubitemid 43849164)
96. Wang GH, Garvey TL, Cohen JI. The murine gammaherpesvirus-68 M11 protein inhibits Fas-and TNF-induced apoptosis. J Gen Virol. 1999;80(Pt 10):2737-40. (Pubitemid 29458636)
97. Ku B, et al. Structural and biochemical bases for the inhibition of autophagy and apoptosis by viral BCL-2 of murine gamma-herpesvirus. PLoS Pathog. 2008;4(2):e25
98. Feng P, et al. A novel inhibitory mechanism of mitochondrion-dependent apoptosis by a herpesviral protein. PLoS Pathog. 2007;3(12):e174.
99. Miller CL, et al. An integral membrane protein (LMP2) blocks reactivation of Epstein-Barr virus from latency following surface immunoglobulin crosslinking. Proc Natl Acad Sci USA. 1994;91(2):772-6. (Pubitemid 24041484)
100. Lan K, et al. Kaposi's sarcoma-associated herpesvirus-encoded latency-associated nuclear antigen inhibits lytic replication by targeting Rta: a potential mechanism for virus-mediated control of latency. J Virol. 2004;78(12):6585-94. (Pubitemid 38715955)
101. Li Q, et al. Genetic disruption of KSHV major latent nuclear antigen LANA enhances viral lytic transcriptional program. Virology. 2008;379(2):234-44.
102. Ye FC, et al. Kaposi's sarcoma-associated herpesvirus latent gene vFLIP inhibits viral lytic replication through NF-kappaB-mediated suppression of the AP-1 pathway: a novel mechanism of virus control of latency. J Virol. 2008;82(9):4235-49.
103. Pfeffer S, et al. Identification of virus-encoded microRNAs. Science. 2004;304(5671):734-6. (Pubitemid 38560879)
104. Boss IW, Plaisance KB, Renne R. Role of virus-encoded microRNAs in herpesvirus biology. Trends Microbiol. 2009;17(12):544-53.
105. Bellare P, Ganem D. Regulation of KSHV lytic switch protein expression by a virus-encoded microRNA: an evolutionary adaptation that fine-tunes lytic reactivation. Cell Host Microbe. 2009;6(6): 570-5.
106. Lu F et al. Epigenetic regulation of Kaposi's sarcoma-associated herpesvirus latency by virus-encoded microRNAs that target Rta and the cellular Rbl2-DNMT pathway. J Virol. 84(6):2697-706.
107. Rooney CM, et al. Adoptive immunotherapy of EBV-associated malignancies with EBV-specific cytotoxic T-cell lines. Curr Top Microbiol Immunol. 2001;258:221-9. (Pubitemid 32574043)
108. Rooney CM et al. Immunotherapy for Epstein-Barr virus-associated cancers. J Natl Cancer Inst Monogr. 1998;(23):89-93.
109. Steven NM, et al. Immediate early and early lytic cycle proteins are frequent targets of the Epstein-Barr virus-induced cytotoxic T cell response. J Exp Med. 1997;185(9):1605-17. (Pubitemid 27203257)
110. Pudney VA, et al. CD8? immunodominance among Epstein-Barr virus lytic cycle antigens directly reflects the efficiency of antigen presentation in lytically infected cells. J Exp Med. 2005;201(3): 349-60. (Pubitemid 40229410)
111. Woodberry T, et al. Differential targeting and shifts in the immunodominance of Epstein-Barr virus- specific CD8 and CD4 T cell responses during acute and persistent infection. J Infect Dis. 2005;192(9):1513-24. (Pubitemid 41504686)
112. Landais E, Saulquin X, Houssaint E. The human T cell immune response to Epstein-Barr virus. Int J Dev Biol. 2005;49(2-3):285-92. (Pubitemid 40917350)
113. Steven NM, et al. Epitope focusing in the primary cytotoxic T cell response to Epstein-Barr virus and its relationship to T cell memory. J Exp Med. 1996;184(5):1801-13. (Pubitemid 26404471)
114. Levitskaya J, et al. Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. Nature. 1995;375(6533):685-8.
115. Levitskaya J, et al. Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. Proc Natl Acad Sci USA. 1997; 94(23):12616-21. (Pubitemid 27492577)
116. Yin Y, Manoury B, Fahraeus R. Self-inhibition of synthesis and antigen presentation by Epstein-Barr virus-encoded EBNA1. Science. 2003;301(5638):1371- 4. (Pubitemid 37075811)
117. Schubert U, et al. Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. Nature. 2000;404(6779):770-4. (Pubitemid 30212405)
118. Reits EA, et al. The major substrates for TAP in vivo are derived from newly synthesized proteins. Nature. 2000;404(6779):774-8. (Pubitemid 30212406)
119. Lee SP, et al. CD8 T cell recognition of endogenously expressed Epstein-Barr virus nuclear antigen 1. J Exp Med. 2004;199(10):1409-20. (Pubitemid 38685732)
120. Voo KS, et al. Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8 ? T lymphocytes. J ExpMed. 2004;199(4):459-70. (Pubitemid 38233830)
121. Tellam J, et al. Endogenous presentation of CD8 ? T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. J Exp Med. 2004;199(10):1421-31. (Pubitemid 38685733)
122. Saulquin X, et al. A global appraisal of immunodominant CD8 T cell responses to Epstein-Barr virus and cytomegalovirus by bulk screening. Eur J Immunol. 2000;30(9):2531-9.
123. Tan LC, et al. A re-evaluation of the frequency of CD8 ? T cells specific for EBV in healthy virus carriers. J Immunol. 1999;162(3):1827-35. (Pubitemid 29307064)
124. Murray RJ, et al. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): implications for the immune control of EBV-positive malignancies. J Exp Med. 1992;176(1):157-68.
125. Khanna R, et al. Localization of Epstein-Barr virus cytotoxic T cell epitopes using recombinant vaccinia: implications for vaccine development. J Exp Med. 1992;176(1):169-76.
126. Meij P, et al. Identification and prevalence of CD8(?) T-cell responses directed against Epstein-Barr virus-encoded latent membrane protein 1 and latent membrane protein 2. Int J Cancer. 2002; 99(1):93-9. (Pubitemid 34273204)
127. Wang QJ, et al. Primary human herpesvirus 8 infection generates a broadly specific CD8(?) T-cell response to viral lytic cycle proteins. Blood. 2001;97(8):2366-73. (Pubitemid 32291483)
128. Lambert M, et al. Differences in the frequency and function of HHV8-specific CD8 T cells between asymptomatic HHV8 infection and Kaposi sarcoma. Blood. 2006;108(12):3871-80. (Pubitemid 44864571)
129. Robey RC, et al. The CD8 and CD4 T-cell response against Kaposi's sarcoma-associated herpesvirus is skewed towards early and late lytic antigens. PLoS One. 2009;4(6):e5890.
130. Zaldumbide A, et al. In cis inhibition of antigen processing by the latency-associated nuclear antigen I of Kaposi sarcoma herpes virus. Mol Immunol. 2007;44(6):1352-60. (Pubitemid 44415957)
131. Guihot A, et al. Low T cell responses to human herpesvirus 8 in patients with AIDS-related and classic Kaposi sarcoma. J Infect Dis. 2006;194(8):1078-88. (Pubitemid 44547647)
132. Brander C, et al. Definition of an optimal cytotoxic T lymphocyte epitope in the latently expressed Kaposi's sarcoma-associated herpesvirus kaposin protein. J Infect Dis. 2001;184(2):119-26. (Pubitemid 32614039)
133. Freeman ML, et al. Two kinetic patterns of epitope-specific CD8 T-cell responses following murine gammaherpesvirus 68 infection. J Virol. 2010;84(6):2881-92.
134. Gredmark-Russ S, et al. The CD8 T-cell response against murine gammaherpesvirus 68 is directed toward a broad repertoire of epitopes from both early and late antigens. J Virol. 2008;82(24): 12205-12.
135. Aichinger G, et al. Major histocompatibility complex class II-dependent unfolding, transport, and degradation of endogenous proteins. J Biol Chem. 1997;272(46):29127-36. (Pubitemid 27498202)
136. Paludan C, et al. Endogenous MHC class II processing of a viral nuclear antigen after autophagy. Science. 2005;307(5709):593-6. (Pubitemid 40165684)
137. Brown DM. Cytolytic CD4 cells: direct mediators in infectious disease and malignancy. Cell Immunol. 2010;262(2):89-95.
138. Nikiforow S, et al. Cytolytic CD4(?)-T-cell clones reactive to EBNA1 inhibit Epstein-Barr virusinduced B-cell proliferation. J Virol. 2003;77(22):12088-104. (Pubitemid 37339862)
139. Long HM, et al. CD4 + T-cell responses to Epstein-Barr virus (EBV) latent-cycle antigens and the recognition of EBV-transformed lymphoblastoid cell lines. J Virol. 2005;79(8):4896-907. (Pubitemid 40464240)
140. Paludan C, et al. Epstein-Barr nuclear antigen 1-specific CD4(+) Th1 cells kill Burkitt's lymphoma cells. J Immunol. 2002;169(3):1593-603. (Pubitemid 34809208)
141. Landais E, et al. Direct killing of Epstein-Barr virus (EBV)-infected B cells by CD4 T cells directed against the EBV lytic protein BHRF1. Blood. 2004;103(4):1408-16. (Pubitemid 38168656)
142. Omiya R, et al. Inhibition of EBV-induced lymphoproliferation by CD4(+) T cells specific for an MHC class II promiscuous epitope. J Immunol. 2002;169(4):2172-9. (Pubitemid 34857685)
143. Leen A, et al. Differential immunogenicity of Epstein-Barr virus latent-cycle proteins for human CD4(+) T-helper 1 responses. J Virol. 2001;75(18):8649-59. (Pubitemid 32768969)
144. Munz C, et al. Human CD4(?) T lymphocytes consistently respond to the latent Epstein-Barr virus nuclear antigen EBNA1. J Exp Med. 2000;191(10):1649- 60. (Pubitemid 30331564)
145. Bickham K, et al. EBNA1-specific CD4 + T cells in healthy carriers of Epstein-Barr virus are primarily Th1 in function. J Clin Invest. 2001;107(1):121-30. (Pubitemid 32047421)
146. Moormann AM, et al. Children with endemic Burkitt lymphoma are deficient in EBNA1-specific IFNgamma T cell responses. Int J Cancer. 2009;124(7):1721-6.
147. Heller KN, et al. Patients with Epstein Barr virus-positive lymphomas have decreased CD4(+) T-cell responses to the viral nuclear antigen 1. Int J Cancer. 2008;123(12):2824-31.
148. Haigh TA, et al. EBV latent membrane proteins (LMPs) 1 and 2 as immunotherapeutic targets: LMPspecific CD4 + cytotoxic T cell recognition of EBV-transformed B cell lines. J Immunol. 2008; 180(3):1643-54.
149. Adhikary D, et al. Control of Epstein-Barr virus infection in vitro by T helper cells specific for virion glycoproteins. J Exp Med. 2006;203(4):995-1006.
150. Wallace LE, et al. Identification of two T-cell epitopes on the candidate Epstein-Barr virus vaccine glycoprotein gp340 recognized by CD4 + T-cell clones. J Virol. 1991;65(7):3821-8.
151. Christensen JP, Doherty PC. Quantitative analysis of the acute and long-term CD4(+) T-cell response to a persistent gammaherpesvirus. J Virol. 1999;73(5):4279-83. (Pubitemid 29189874)
152. Cardin RD, et al. Progressive loss of CD8 + T cell-mediated control of a gamma-herpesvirus in the absence of CD4 + T cells. J Exp Med. 1996;184(3):863-71.
153. Christensen JP, et al. CD4(+) T cell-mediated control of a gamma-herpesvirus in B cell-deficient mice is mediated by IFN-gamma. Proc Natl Acad Sci USA. 1999;96(9):5135-40. (Pubitemid 29214548)
154. Stuller KA, Flano E. CD4 T cells mediate killing during persistent gammaherpesvirus 68 infection. J Virol. 2009;83(9):4700-3.
155. Stuller KA, Cush SS, Flano E. Persistent gamma-herpesvirus infection induces a CD4 T cell response containing functionally distinct effector populations. J Immunol. 2010;184(7):3850-6.
156. Flano E, et al. Analysis of virus-specific CD4(+) t cells during long-term gammaherpesvirus infection. J Virol. 2001;75(16):7744-8. (Pubitemid 32738035)
157. Thorley-Lawson DA, Poodry CA. Identification and isolation of the main component (gp350-gp220) of Epstein-Barr virus responsible for generating neutralizing antibodies in vivo. J Virol. 1982;43(2): 730-6. (Pubitemid 12096345)
158. Yao QY, et al. Salivary and serum IgA antibodies to the Epstein-Barr virus glycoprotein gp340: incidence and potential for virus neutralization. Int J Cancer. 1991;48(1):45-50.
159. Khanna R, Burrows SR, Moss DJ. Immune regulation in Epstein-Barr virus-associated diseases. Microbiol Rev. 1995;59(3):387-405.
160. Henle G, Henle W. Epstein-Barr virus-specific IgA serum antibodies as an outstanding feature of nasopharyngeal carcinoma. Int J Cancer. 1976;17(1):1-7.
161. Kimball LE, et al. Reduced levels of neutralizing antibodies to Kaposi sarcoma-associated herpesvirus in persons with a history of Kaposi sarcoma. J Infect Dis. 2004;189(11):2016-22. (Pubitemid 38692281)
162. Stevenson PG, Doherty PC. Kinetic analysis of the specific host response to a murine gammaherpesvirus. J Virol. 1998;72(2):943-9. (Pubitemid 28116871)
163. Doherty PC, et al. Dissecting the host response to a gamma-herpesvirus. Philos Trans R Soc Lond B Biol Sci. 2001;356(1408):581-93.
164. Kim IJ, et al. Antibody-mediated control of persistent gamma-herpesvirus infection. J Immunol. 2002;168(8):3958-64.
165. Stevenson PG, et al. Immunological control of a murine gammaherpesvirus independent of CD8 + T cells. J Gen Virol. 1999;80(Pt 2):477-83. (Pubitemid 29095210)
166. Tibbetts SA, et al. Effective vaccination against long-term gammaherpesvirus latency. J Virol. 2003;77(4):2522-9. (Pubitemid 36222776)
167. Bennett NJ, May JS, Stevenson PG. Gamma-herpesvirus latency requires T cell evasion during episome maintenance. PLoS Biol. 2005;3(4):e120.
168. Ressing ME, et al. Epstein-Barr virus evasion of CD8(+) and CD4(+) T cell immunity via concerted actions of multiple gene products. Semin Cancer Biol. 2008;18(6):397-408.
169. Liang C, Lee JS, Jung JU. Immune evasion in Kaposi's sarcoma-associated herpes virus associated oncogenesis. Semin Cancer Biol. 2008;18(6):423-36.
170. Coscoy L. Immune evasion by Kaposi's sarcoma-associated herpesvirus. Nat Rev Immunol. 2007; 7(5):391-401. (Pubitemid 46674490)
171. Rezaee SA, et al. Kaposi's sarcoma-associated herpesvirus immune modulation: an overview. J Gen Virol. 2006;87(Pt 7):1781-804. (Pubitemid 43985863)
172. Areste C, Blackbourn DJ. Modulation of the immune system by Kaposi's sarcoma-associated herpesvirus. Trends Microbiol. 2009;17(3):119-29.
173. Stevenson PG. Immune evasion by gamma-herpesviruses. Curr Opin Immunol. 2004;16(4): 456-62. (Pubitemid 38881673)
174. Zuo J, et al. The DNase of gammaherpesviruses impairs recognition by virus-specific CD8 + T cells through an additional host shutoff function. J Virol. 2008;82(5):2385-93. (Pubitemid 351293539)
175. Rowe M, et al. Host shutoff during productive Epstein-Barr virus infection is mediated by BGLF5 and may contribute to immune evasion. Proc Natl Acad Sci USA. 2007;104(9):3366-71. (Pubitemid 46364165)
176. Liang C, E X, Jung JU. Downregulation of autophagy by herpesvirus Bcl-2 homologs. Autophagy. 2008;4(3):268-72. (Pubitemid 351458084)
177. Pattingre S, et al. Bcl-2 antiapoptotic proteins inhibit Beclin 1-dependent autophagy. Cell. 2005; 122(6):927-39. (Pubitemid 41345209)
178. Dengjel J, et al. Autophagy promotes MHC class II presentation of peptides from intracellular source proteins. Proc Natl Acad Sci USA. 2005;102(22):7922-7. (Pubitemid 40781039)
179. Moore KW, et al. Homology of cytokine synthesis inhibitory factor (IL-10) to the Epstein-Barr virus gene BCRFI. Science. 1990;248(4960):1230-4.
180. Bridgeman A, et al. A secreted chemokine binding protein encoded by murine gammaherpesvirus-68 is necessary for the establishment of a normal latent load. J Exp Med. 2001;194(3):301-12. (Pubitemid 32730804)
181. Kledal TN, et al. A broad-spectrum chemokine antagonist encoded by Kaposi's sarcoma-associated herpesvirus. Science. 1997;277(5332):1656-9. (Pubitemid 27446226)
182. Sozzani S, et al. The viral chemokine macrophage inflammatory protein-II is a selective Th2 chemoattractant. Blood. 1998;92(11):4036-9. (Pubitemid 28544316)
183. Stine JT, et al. KSHV-encoded CC chemokine vMIP-III is a CCR4 agonist, stimulates angiogenesis, and selectively chemoattracts TH2 cells. Blood. 2000;95(4):1151-7. (Pubitemid 30099820)
184. Moore KW, et al. Interleukin-10. Annu Rev Immunol. 1993;11:165-90. (Pubitemid 23115005)
185. Nachmani D, et al. Diverse herpesvirus microRNAs target the stress-induced immune ligand MICB to escape recognition by natural killer cells. Cell Host Microbe. 2009;5(4):376-85.
186. Levin MJ, et al. Immune response of elderly individuals to a live attenuated varicella vaccine. J Infect Dis. 1992;166(2):253-9.
187. Oxman MN, et al. A vaccine to prevent herpes zoster and postherpetic neuralgia in older adults. N Engl J Med. 2005;352(22):2271-84.
188. Hoffman GJ, Lazarowitz SG, Hayward SD. Monoclonal antibody against a 250,000-dalton glycoprotein of Epstein-Barr virus identifies a membrane antigen and a neutralizing antigen. Proc Natl Acad Sci USA. 1980;77(5):2979-83. (Pubitemid 10049861)
189. Epstein MA, et al. Protection of cottontop tamarins against Epstein-Barr virus-induced malignant lymphoma by a prototype subunit vaccine. Nature. 1985;318(6043):287-9. (Pubitemid 16206730)
190. Morgan AJ, et al. Recombinant vaccinia virus expressing Epstein-Barr virus glycoprotein gp340 protects cottontop tamarins against EB virus-induced malignant lymphomas. J Med Virol. 1988; 25(2):189-95.
191. Ragot T, et al. Replication-defective recombinant adenovirus expressing the Epstein-Barr virus (EBV) envelope glycoprotein gp340/220 induces protective immunity against EBV-induced lymphomas in the cottontop tamarin. J Gen Virol. 1993;74(Pt 3):501-7. (Pubitemid 23092905)
192. Gu SY, et al. First EBV vaccine trial in humans using recombinant vaccinia virus expressing the major membrane antigen. Dev Biol Stand. 1995;84:171-7.
193. Chang H, et al. Non-human primate model of Kaposi's sarcoma-associated herpesvirus infection. PLoS Pathog. 2009;5(10):e1000606.
194. Mansfield KG, et al. Experimental infection of rhesus and pig-tailed macaques with macaque rhadinoviruses. J Virol. 1999;73(12):10320-8.
195. Moghaddam A, et al. An animal model for acute and persistent Epstein-Barr virus infection. Science. 1997;276(5321):2030-3. (Pubitemid 27443605)
196. Dittmer D, et al. Experimental transmission of Kaposi's sarcoma-associated herpesvirus (KSHV/ HHV-8) to SCID-hu Thy/Liv mice. J Exp Med. 1999;190(12):1857-68. (Pubitemid 30013851)
197. Islas-Ohlmayer M, et al. Experimental infection of NOD/SCID mice reconstituted with human CD34 ? cells with Epstein-Barr virus. J Virol. 2004;78(24):13891-900. (Pubitemid 39612786)
198. Yajima M, et al. A new humanized mouse model of Epstein-Barr virus infection that reproduces persistent infection, lymphoproliferative disorder, and cell-mediated and humoral immune responses. J Infect Dis. 2008;198(5):673-82.
199. Melkus MW, et al. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat Med. 2006;12(11):1316-22. (Pubitemid 44706935)
200. Yajima M, et al. T cell-mediated control of Epstein-Barr virus infection in humanized mice. J Infect Dis. 2009;200(10):1611-5.
201. Traggiai E, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science. 2004;304(5667):104-7. (Pubitemid 38451466)
202. Obar JJ, et al. T-cell responses to the M3 immune evasion protein of murid gammaherpesvirus 68 are partially protective and induced with lytic antigen kinetics. J Virol. 2004;78(19):10829-32. (Pubitemid 39258409)
203. Woodland DL, et al. Vaccination against murine gamma-herpesvirus infection. Viral Immunol. 2001;14(3):217-26. (Pubitemid 32852057)
204. Usherwood EJ, et al. Latent antigen vaccination in a model gammaherpesvirus infection. J Virol. 2001;75(17):8283-8. (Pubitemid 32743700)
205. Stewart JP, et al. Murine gamma-herpesvirus 68 glycoprotein 150 protects against virus-induced mononucleosis: a model system for gamma-herpesvirus vaccination. Vaccine. 1999;17(2):152-7. (Pubitemid 28494114)
206. Stevenson PG, et al. A gamma-herpesvirus sneaks through a CD8(?) T cell response primed to a lyticphase epitope. Proc Natl Acad Sci USA. 1999;96(16):9281-6. (Pubitemid 29374746)
207. Liu L, et al. T-cell vaccination alters the course of murine herpesvirus 68 infection and the establishment of viral latency in mice. J Virol. 1999;73(12):9849-57.
208. Stewart JP, et al. In vivo function of a gammaherpesvirus virion glycoprotein: influence on B-cell infection and mononucleosis. J Virol. 2004;78(19):10449-59. (Pubitemid 39258370)
209. Arico E, et al. Vaccination with inactivated murine gammaherpesvirus 68 strongly limits viral replication and latency and protects type I IFN receptor knockout mice from a lethal infection. Vaccine. 2004;22(11-12):1433-40. (Pubitemid 38446919)
210. Fowler P, Efstathiou S. Vaccine potential of a murine gammaherpesvirus-68 mutant deficient for ORF73. J Gen Virol. 2004;85(Pt 3):609-13. (Pubitemid 38379862)
211. Rickabaugh TM, et al. Generation of a latency-deficient gammaherpesvirus that is protective against secondary infection. J Virol. 2004;78(17):9215-23. (Pubitemid 39096531)
212. Boname JM, et al. Protection against wild-type murine gammaherpesvirus-68 latency by a latencydeficient mutant. J Gen Virol. 2004;85(Pt 1):131-5. (Pubitemid 38128877)
213. Jia Q et al. Induction of protective immunity against murine gammaherpesvirus-68 infection in the absence of viral latency. J Virol. 2009.
214. May JS, et al. Forced lytic replication impairs host colonization by a latency-deficient mutant of murine gammaherpesvirus-68. J Gen Virol. 2004;85(Pt 1):137-46. (Pubitemid 38128878)
215. Zuo J, et al. The Epstein-Barr virus G-protein-coupled receptor contributes to immune evasion by targeting MHC class I molecules for degradation. PLoS Pathog. 2009;5(1):e1000255.
216. Hislop AD, et al. A CD8 ? T cell immune evasion protein specific to Epstein-Barr virus and its close relatives in Old World primates. J Exp Med. 2007;204(8):1863-73. (Pubitemid 47236322)
217. Wang JT, et al. Epstein-Barr virus BGLF4 kinase suppresses the interferon regulatory factor 3 signaling pathway. J Virol. 2009;83(4):1856-69.
218. Bentz GL, et al. Epstein-Barr virus BRLF1 inhibits transcription of IRF3 and IRF7 and suppresses induction of interferon-beta. Virology. 2010;402(1):121-8.
219. Wu L, et al. Epstein-Barr virus LF2: an antagonist to type I interferon. J Virol. 2009;83(2):1140-6.
220. Ishido S, et al. Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. J Virol. 2000;74(11):5300-9. (Pubitemid 30313872)
221. Coscoy L, Ganem D. Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. Proc Natl Acad Sci USA. 2000;97(14):8051-6. (Pubitemid 30460771)
222. Hwang S, et al. Conserved herpesviral kinase promotes viral persistence by inhibiting the IRF-3-mediated type I interferon response. Cell Host Microbe. 2009;5(2):166-78.
223. Yu Y, Wang SE, Hayward GS. The KSHV immediate-early transcription factor RTA encodes ubiquitin E3 ligase activity that targets IRF7 for proteosome-mediated degradation. Immunity. 2005;22(1):59-70. (Pubitemid 40143451)
224. Zhu FX, et al. A Kaposi's sarcoma-associated herpesviral protein inhibits virus-mediated induction of type I interferon by blocking IRF-7 phosphorylation and nuclear accumulation. Proc Natl Acad Sci USA. 2002;99(8):5573-8. (Pubitemid 34411590)
225. Areste C, Mutocheluh M, Blackbourn DJ. Identification of caspase-mediated decay of interferon regulatory factor-3, exploited by a Kaposi sarcoma-associated herpesvirus immunoregulatory protein. J Biol Chem. 2009;284(35):23272-85.
226. Wies E, et al. The Kaposi's Sarcoma-associated Herpesvirus-encoded vIRF-3 inhibits cellular IRF-5. J Biol Chem. 2009;284(13):8525-38.
227. Fuld S, et al. Inhibition of interferon signaling by the Kaposi's sarcoma-associated herpesvirus fulllength viral interferon regulatory factor 2 protein. J Virol. 2006;80(6):3092-7. (Pubitemid 43346406)
228. Lin R, et al. HHV-8 encoded vIRF-1 represses the interferon antiviral response by blocking IRF-3 recruitment of the CBP/p300 coactivators. Oncogene. 2001;20(7):800-11. (Pubitemid 32198173)
229. Burysek L, et al. Functional analysis of human herpesvirus 8-encoded viral interferon regulatory factor 1 and its association with cellular interferon regulatory factors and p300. J Virol. 1999;73(9):7334-42. (Pubitemid 29383216)
230. Burysek L, Yeow WS, Pitha PM. Unique properties of a second human herpesvirus 8-encoded interferon regulatory factor (vIRF-2). J Hum Virol. 1999;2(1):19-32. (Pubitemid 30261694)
231. Bisson SA, Page AL, Ganem D. A Kaposi's sarcoma-associated herpesvirus protein that forms inhibitory complexes with type I interferon receptor subunits, Jak and STAT proteins, and blocks interferon-mediated signal transduction. J Virol. 2009;83(10):5056-66.
232. Boname JM, et al. Viral degradation of the MHC class I peptide loading complex. Immunity. 2004;20(3):305-17. (Pubitemid 38388232)